Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NDI-5001 in X-linked Congenital Nephrogenic Diabetes Insipidus
NCT07525960Phase 1Recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NDI-5001 in congenital nephrogenic diabetes insipidus (cNDI), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Percentage Change From Baseline in 24-Hour Urine Volume and Percentage Change From Baseline in Spot Urine Osmolality. Started Jul 2026; status: recruiting.
02
Drugs
NDI-5001
03
Conditions
congenital nephrogenic diabetes insipidus (cNDI)
Beyond the preview
Go deeper on NCT07525960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07525960.